Company news

Oryzon Genomics SA news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches

December 16, 2022

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

November 9, 2022

ORYZON Announces Oral Data Presentation at the Upcoming 64th American Society of Hematology Annual Conference

November 7, 2022

ORYZON to Give Updates on Corporate Progress in November

November 4, 2022

ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2022

November 2, 2022

ORYZON to Give Updates on Corporate Progress in October

October 3, 2022

ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

September 16, 2022

ORYZON Collaborates with the CMT Research Foundation in the US

July 26, 2022

ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022

July 22, 2022

ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers

July 19, 2022

ORYZON at EHA-2022: Iadademstat 42-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

June 10, 2022

ORYZON Awarded EU Seal of Excellence and Public Financing of $2M USD to Develop Iadademstat in Acute Myeloid Leukemia

June 7, 2022

ORYZON to Give Updates on Corporate Progress in June

June 6, 2022

ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2022

May 5, 2022

ORYZON Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

May 3, 2022

ORYZON to Give Updates on Corporate Progress in February and March

February 14, 2022

ORYZON Reports Results and Corporate Update for Q4 and Year Ended December 31, 2021

February 7, 2022

ORYZON Announces New Senior VP of Clinical Development and Global Medical Affairs, Continuing its Expansion of US Corporate Activities

January 11, 2022

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

January 4, 2022

ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in November and December

November 9, 2021

ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2021

October 28, 2021

ORYZON enrolls first patient in the US in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder

October 18, 2021

ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in September and October

September 22, 2021

Oryzon Announces $1 Million Grant From Kabuki Syndrome Philanthropists to Support a Precision Medicine Phase I/II Trial With Vafidemstat

September 21, 2021

ORYZON Reports Results and Corporate Update for First Half Ended June 30, 2021

July 29, 2021

ORYZON Presents Safety and Efficacy Data of Vafidemstat From the Phase II ESCAPE Trial in Severe COVID-19 Patients at ECCMID-2021

July 9, 2021

ORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Borderline Personality Disorder

June 15, 2021

ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2021

May 7, 2021

ORYZON Starts Preclinical Collaboration on Autism with the Seaver Autism Center at Mount Sinai

April 6, 2021

ORYZON Enrolls First Patient in PORTICO, a Phase IIb Clinical Trial With Vafidemstat in Borderline Personality Disorder

March 29, 2021

ORYZON Publishes Vafidemstat First-in-Human Clinical Trial Manuscript in CNS Drugs Journal

March 24, 2021

ORYZON Presents vafidemstat 12-month Clinical Data From its Phase IIa Clinical Trials ETHERAL and REIMAGINE-AD in Alzheimer’s at the Virtual AD/PD-2021 Conference

March 9, 2021

ORYZON Reports Results and Corporate Update for 4th Quarter and Year Ended December 31, 2020

February 23, 2021

ORYZON to Present a Corporate Update and to Hold Multiple Virtual Corporate Activities in January 2021

January 4, 2021

ORYZON Presents New Robust Phase II Iadademstat Efficacy Data in AML at ASH-2020

December 7, 2020

ORYZON Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

November 10, 2020

Oryzon Announces Appointment of Dr. Torsten Hoffmann as Global R&D Director and Retirement of Dr. Tamara Maes

November 2, 2020

ORYZON Reports Results for Quarter Ended September 30, 2020 and Provides Corporate Update

October 26, 2020

ORYZON Publishes Paper in Journal of Clinical Oncology Demonstrating Relevance of Iadademstat in Leukemia

October 15, 2020

ORYZON First Half Ended June 30, 2020 Results and Corporate Update

July 22, 2020

ORYZON Raises its Share Capital by EUR 20 Million

July 7, 2020

ORYZON Enters Into Pioneering Precision Medicine Collaboration with La Paz Hospital in Madrid for Phelan-McDermid Syndrome

June 19, 2020

ORYZON to Present Additional Efficacy Clinical Data From ALICE Phase IIa Trial with Iadademstat at the 25th Congress of the European Hematology Association

June 2, 2020

ORYZON Publishes Characterization and Mechanism of Action of Vafidemstat, a Phase II Clinical Stage LSD1 Inhibitor, in PLOS ONE

June 1, 2020

ORYZON Announces Enrollment of First Patient in ESCAPE: a Phase II Clinical Trial with Vafidemstat in Severely Ill COVID-19 Patients

May 18, 2020

ORYZON Appoints Manuel López-Figueroa of Bay City Capital to its Board of Directors

May 11, 2020

ORYZON First Quarter 2020 Results and Corporate Update

May 11, 2020

ORYZON to Initiate ESCAPE: a Phase II Clinical Trial to Test Efficacy of Vafidemstat in Severely ill COVID-19 Patients

April 24, 2020

ORYZON Provides a Corporate Update in the Context of COVID-19

April 17, 2020

ORYZON Appoints Eisai Executive Vanessa Almendro Navarro to Board of Directors

April 17, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 18 decks. Every deck is listed under its year.